Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
japanese encephalitis vaccine (live attenuated)
- Development stage
- Phase 4
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Japanese encephalitis vaccine (live attenuated) is a biologic used to prevent Japanese encephalitis (JE), a severe mosquito-borne viral infection. The vaccine primarily exists in two forms: the **SA14-14-2** strain, which is a live attenuated virus generated by serial passage in primary hamster kidney cells, and the **ChimeriVax-JE** (IMOJEV) technology, which is a recombinant chimeric vaccine using a yellow fever virus (YF17D) backbone expressing the envelope and pre-membrane proteins of the Japanese encephalitis virus (JEV). Both formulations work by stimulating the immune system to produce neutralizing antibodies against the JEV envelope protein, providing high efficacy (over 99%) and long-term protection. It is widely administered in endemic regions, particularly across Asia, as a single subcutaneous dose in children and adults.
- Brand names
- IMOJEVCD.JEVAX
- Other names
- Live attenuated Japanese encephalitis virus vaccineJEV vaccine (live)SA14-14-2 vaccineSA-14-14-2 vaccineSA 14-14-2 vaccine
Beyond the preview
Go deeper on japanese encephalitis vaccine (live attenuated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on japanese encephalitis vaccine (live attenuated).